1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Canada >
  5. Ontario >
  6. AstraZeneca Acquires Fusion Pharmaceuticals

M&A Deal Summary

AstraZeneca Acquires Fusion Pharmaceuticals

On March 19, 2024, AstraZeneca acquired life science company Fusion Pharmaceuticals for 2.4B USD

Acquisition Highlights
  • This is AstraZeneca’s 18th transaction in the Life Science sector.
  • This is AstraZeneca’s 6th largest (disclosed) transaction.
  • This is AstraZeneca’s 2nd transaction in Canada.
  • This is AstraZeneca’s 1st transaction in Ontario.

M&A Deal Summary
Date 2024-03-19
Target Fusion Pharmaceuticals
Sector Life Science
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 2.4B USD

Target

Fusion Pharmaceuticals

Hamilton, Ontario, Canada
Fusion Pharmaceuticals is a pharmaceutical company focused on the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. Fusion Pharmaceuticals was formed in 2014 and is based in Hamilton, Ontario.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 54.1B USD (2024)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 20 of 23
Sector: Life Science M&A 18 of 21
Type: Add-on Acquisition M&A Deals 16 of 17
State: Ontario M&A 1 of 1
Country: Canada M&A 2 of 2
Year: 2024 M&A 2 of 3
Size (of disclosed) 6 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-14 Amolyt Pharma

Ecully, France

Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France.

Buy $1.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-24 TRACERx

London, United Kingdom

TRACERx is a tumor evolution study to generate deep sequencing multi-region and multi-time point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. TRACERx is based in London, United Kingdom.

Buy -
Mergr

Solution for

Product

Company

Legal